CyBeR Association in Relapsed/Refractory DLBCL

University Hospital, Caen78 enrolled

Overview

Forty percent of patients with diffuse large B cell lymphoma (DLBCL) have primary refractory or relapsed disease (R/R). For these fit patients, standard treatment in second line therapy is high dose therapy with autologous stem cell transplantation (ASCT). In 48% of DLBCL no ASCT is possible due to progressive disease. For these patients or ineligible to transplantation patients, salvage therapy is often rituximab-gemcitabine-oxaliplatine regimen with an overall response rate (ORR) about 50%. Bendamustine in combination with rituximab, used as a single agent in the setting of R/R DLBCL patients, have shown an ORR of 62.7% and 45.8% with a good safety profile. Bendamustine and cytarabine (BAC) showed high synergy in inducing cell death in mantle cell lymphoma and DLBCL cell lines. In a recent phase II study, the combination of cytarabine with Rituximab and Bendamustine (R-BAC) in patients with mantle cell lymphoma who were previously untreated, refractory or relapsed was evaluated. The efficacy and safety of the R-BAC association will be evaluated in this phase II trial enrolling 78 patients with relapsed or refractory DLBCL.

Participants will received 6 cycles every 21 days with a follow-up period of 24 months. CT-Scan after 3 cycles and at the end of the treatment will be used to assess treatment response, established with Cheson criteria in 1999. Principal objective is to obtain an overall response rate of 60% (corresponding to an increased of 15% of the rituximab-gemcitabine-oxaliplatine regimen's overall response rate). Secondaries objectives are to value toxicity, progression free survival and overall survival.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. patients from 18 to 75 years 2. Patient sharpened the social security system 3. Patients with relapsed or refractory diffuse large B cell lymphoma who received at least one prior line of immunochemotherapy unfit for intensive regimen therapy and autologous stem cell transplantation (ASCT) eligible patients to stem cell transplantation with failure of the salvage therapy patients with relapse after ASCT 4. Not previously treated with bendamustine 5. WHO performance status 0, 1 or 2 6. Adequate hematological function as defined by: leucocyte count ≥ 3.0 109/L, platelet count ≥ 75 109/L 7. Females of childbearing potential must agree to have a medically acceptable method of contraception from study treatment initiation until the end of treatment. 8. Signed informed consent. Exclusion Criteria: 1. Person under guardianship or curatorship , or unable to understand the purpose of the study 2. Central nervous system or meningeal involvement 3. WHO performance status more than 2 4. Contraindication to any drug contained in the chemotherapy regimen 5. HIV disease, active hepatitis B or C 6. Any serious active disease or co-morbid medical condition 7. Any of the following laboratory abnormalities. * Leucocyte count \< 3.0 x 109/L * Platelet count \< 75 x 109/L 8. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form. 9. Pregnant or lactating females. 10. Prior history of malignancies, other than lymphoma, unless the patient has been free of the disease for ≥ 3 years. Exceptions include the following: * Basal cell carcinoma of the skin. * Squamous cell carcinoma of the skin. * Carcinoma in situ of the cervix. * Carcinoma in situ of the breast. * Incidental histological finding of prostate cancer (TNM stage of T1a or T1b). 11. renal impairment with an estimated (modified dietin renal disease; MDRD) creatinine clearance \< 40 ml/min, 12. chronic liver disease or day-1 (AST/ALT )≥2.5 upper limit of normal (ULN), total bilirubin≥1.5 ULN,

Outcomes

Primary Outcomes

treatment response

established with 1999 Cheson criteria on CT-scan

Time frame: up to 20 weeks (at the end of the treatment)

Secondary Outcomes

overall survival

Time frame: 2 years

progression free survival